Antiretroviral drug use and HIV drug resistance among HIV-infected black men who have sex with men: HIV prevention trials network 061

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 4, 2015, Pages 446-452

  Chen, Iris ^a   Connor, Matthew B ^b   Clarke, William ^a   Marzinke, Mark A ^a   Cummings, Vanessa ^a   Breaud, Autumn ^a   Fogel, Jessica M ^a   Laeyendecker, Oliver ^a,c   Fields, Sheldon D ^d   Donnell, Deborah ^b,e   Griffith, Sam ^f   Scott, Hyman M ^g   Shoptaw, Steven ^h   Del Rio, Carlos ⁱ   Magnus, Manya ^j   Mannheimer, Sharon ^k   Wheeler, Darrell P ^l   Mayer, Kenneth H ^m,n,o   Koblin, Beryl A ^p   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f FAMILY HEALTH INTERNATIONAL   (United States)

^g SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ EMORY UNIVERSITY   (United States)

^j GEORGE WASHINGTON UNIVERSITY   (United States)

^k Department of Medicine   (United States)

^l LOYOLA UNIVERSITY CHICAGO   (United States)

^m FENWAY INSTITUTE   (United States)

ⁿ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^o HARVARD MEDICAL SCHOOL   (United States)

^p NEW YORK BLOOD CENTER   (United States)

more..

Author keywords

Antiretroviral drug; Black; Drug resistance; HIV; Men who have sex with men

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BLACK PERSON; CONFERENCE PAPER; DRUG DETERMINATION; DRUG USE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SELF REPORT; SEROCONVERSION; VIRUS LOAD; AFRICAN AMERICAN; GENETICS; HIV INFECTIONS; MALE HOMOSEXUALITY; VIROLOGY;

ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE;

EID: 84975321381     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000633     Document Type: Conference Paper

References (36)

1. Centers for Disease Control and Prevention. HIV and AIDS in America: A Snapshot. 2013. Available at: http://www.cdc.gov/nchhstp/newsroom/ docs/HIV-and-AIDS-in-America-A-Snapshot-508.pdf. Accessed July 1, 2013.
2. National Minority AIDS Council. RISE Proud: Combating HIV Among Black Gay and Bisexual. 2013. Available at: http://blackmenrise.org/wp-content/uploads/2013/06/Action-Plan-6.5.13.pdf. Accessed July 3, 2013.
3. Koblin BA, Mayer KH, Eshleman SH, et al. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One. 2013;8:e70413.
4. Mayer KH, Wang L, Koblin B, et al. Concomitant socioeconomic, behavioral, and biological factors associated with the disproportionate HIV infection burden among Black men who have sex with men in 6 U. S. Cities. PLoS One. 2014;9:e87298.
5. Marzinke MA, Clarke W, Wang L, et al. Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection. Clin Infect Dis. 2014;58:117-120.
6. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72:e1-e25.
7. Chen I, Cummings V, Fogel JM, et al. Low-level viremia early in HIV infection. J Acquir Immune Defic Syndr. 2014;67:405-408.
8. Brookmeyer R, Konikoff J, Laeyendecker O, et al. Estimation of HIV incidence using multiple biomarkers. Am J Epidemiol. 2013;177: 264-272.
9. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2014. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/ AdultandAdolescentGL.pdf. Accessed October 17, 2014.
10. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2008. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL001226.pdf. Accessed October 16, 2014.
11. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2009. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL001561.pdf. Accessed October 16, 2014.
12. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24:1203-1212.
13. Hightow-Weidman LB, Hurt CB, Phillips G II, et al. Transmitted HIV-1 drug resistance among young men of color who have sex with men: a multicenter cohort analysis. J Adolesc Health. 2011;48:94-99.
14. Kim D, Ziebell R, Saduvala N, et al. Trend in transmitted HIV-1 ARV drug resistance-associated mutations: 10 HIV surveillance areas, US, 2007-2010. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA; Abstract 149.
15. Ocfemia MC, Saduvala N, Oster AM, et al. HIV-1 drug resistance among men who have sex with men, 11 US Jurisdictions, 2008-2011. 21st Conference on Retroviruses and Opportunistic Infections [CROI abstract 579]. In Special Issue: Abstracts from the 2014 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2014;22:284.
16. U.S. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm312210.htm. Accessed May 7, 2014.
17. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34:875-892.
18. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005; 54:1-20.
19. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
20. Buchacz K, Baker R, Ward DJ, et al. Trends in decline of antiretroviral resistance among ARV-experienced patients in the HIV outpatient study: 1999-2008. AIDS Res Treat. 2012;2012:230290.
21. Paquet AC, Solberg OD, Napolitano LA, et al. A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse-transcriptase and co-receptor tropism database from 2003 to 2012. Antivir Ther. 2014;19:435-441.
22. Eshleman SH, Husnik M, Hudelson S, et al. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS. 2007;21:1165-1174.
23. Gorbach PM, Drumright LN, Javanbakht M, et al. Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr. 2008;47:639-643.
24. Colfax GN, Vittinghoff E, Grant R, et al. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS. 2007;21:239-241.
25. Fogel JM, Wang L, Parsons TL, et al. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013;208:1624-1628.
26. Kahle EM, Kashuba A, Baeten JM, et al. Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr. 2014;65:e90-e94.
27. Minnis AM, Gandham S, Richardson BA, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013; 17:737-747.
28. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011;305: 1327-1335.
29. Li JF, Kim D, Linley L, et al. Sensitive screening reveals widespread underestimation of transmitted HIV drug resistance. Paper presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA; Abstract 87.
30. U.S. Food and Drug Administration. Hepatitis B and C Treatments. 2015. Available at: http://www.fda.gov/ForPatients/Illness/HepatitisBC/ ucm408658.htm. Accessed January 29, 2015.
31. Menendez-Arias L. Evidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndrome. Rev Med Virol. 2011;21:3-17.
32. Inciardi JA, Surratt HL, Kurtz SP, et al. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8:171-183.
33. Davis GP, Surratt HL, Levin FR, et al. Antiretroviral medication: an emerging category of prescription drug misuse. Am J Addict. 2014;23: 519-525.
34. Grelotti DJ, Closson EF, Mimiaga MJ. Pretreatment antiretroviral exposure from recreational use. Lancet Infect Dis. 2013;13:10-12.
35. Kurtz SP, Buttram ME, Surratt HL. Vulnerable infected populations and street markets for ARVs: potential implications for PrEP rollout in the USA. AIDS Care. 2014;26:411-415.
36. Tsuyuki K, Surratt HL, Levi-Minzi MA, et al. The demand for antiretroviral drugs in the illicit marketplace: implications for HIV disease management among vulnerable populations. AIDS Behav. 2015;19(5):857-868.